Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013

Description: Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013

Summary

'Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Central Nervous System (CNS) Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Central Nervous System (CNS) Tumor. Central Nervous System (CNS) Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Central Nervous System (CNS) Tumor.
- A review of the Central Nervous System (CNS) Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Central Nervous System (CNS) Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Central Nervous System (CNS) Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Central Nervous System (CNS) Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

2 Introduction
6 Central Nervous System (CNS) Tumor Overview
8 Therapeutics Development
10 Central Nervous System (CNS) Tumor Therapeutics under Development by Companies
18 Central Nervous System (CNS) Tumor Therapeutics under Investigation by Universities/Institutes
21 Late Stage Products
22 Mid Clinical Stage Products
23 Early Clinical Stage Products
24 Discovery and Pre-Clinical Stage Products
25 Central Nervous System (CNS) Tumor Therapeutics – Products under Development by Companies
Central Nervous System (CNS) Tumor Therapeutics – Products under Investigation by Universities/Institutes

Companies Involved in Central Nervous System (CNS) Tumor Therapeutics Development

Central Nervous System (CNS) Tumor – Therapeutics Assessment

Drug Profiles

Central Nervous System (CNS) Tumor Therapeutics – Drug Profile Updates

Central Nervous System (CNS) Tumor Therapeutics – Discontinued Products

Central Nervous System (CNS) Tumor Therapeutics - Dormant Products

Central Nervous System (CNS) Tumor – Product Development Milestones

Appendix

List of Tables

- Number of Products Under Development for Central Nervous System (CNS) Tumor, H1 2013
- Products under Development for Central Nervous System (CNS) Tumor – Comparative Analysis, H1 2013
- Number of Products under Development by Companies, H1 2013
- Number of Products under Development by Companies, H1 2013 (Contd..1)
- Number of Products under Development by Companies, H1 2013 (Contd..2)
- Number of Products under Development by Companies, H1 2013 (Contd..3)
- Number of Products under Development by Companies, H1 2013 (Contd..4)
- Number of Products under Development by Companies, H1 2013 (Contd..5)
- Number of Products under Development by Companies, H1 2013 (Contd..6)
- Number of Products under Investigation by Universities/Institutes, H1 2013
- Number of Products under Investigation by Universities/Institutes, H1 2013 (Contd..1)
- Comparative Analysis by Late Stage Development, H1 2013
- Comparative Analysis by Mid Clinical Stage Development, H1 2013
- Comparative Analysis by Early Clinical Stage Development, H1 2013
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
- Products under Development by Companies, H1 2013 (Contd..1)
- Products under Development by Companies, H1 2013 (Contd..2)
- Products under Development by Companies, H1 2013 (Contd..3)
- Products under Development by Companies, H1 2013 (Contd..4)
- Products under Development by Companies, H1 2013 (Contd..5)
- Products under Development by Companies, H1 2013 (Contd..6)
- Products under Development by Companies, H1 2013 (Contd..7)
- Products under Development by Companies, H1 2013 (Contd..8)
- Products under Investigation by Universities/Institutes, H1 2013 (Contd..1)
- Johnson & Johnson, H1 2013
- F. Hoffmann-La Roche Ltd., H1 2013
- Amgen Inc., H1 2013
- Sanofi-Aventis, H1 2013
- AstraZeneca PLC, H1 2013
- Eli Lilly and Company, H1 2013
- Genentech, Inc., H1 2013
- Antigenics, Inc., H1 2013
- MedImmune LLC, H1 2013
- Lentigen Corporation, H1 2013
- Sangamo BioSciences, Inc., H1 2013
- Plexxikon Inc., H1 2013
- Celltrion, Inc., H1 2013
- Novartis AG, H1 2013
- Actelion Ltd, H1 2013
- Nippon Shinyaku Co., Ltd., H1 2013
- Pfizer Inc., H1 2013
- Cell Therapeutics, Inc., H1 2013
- Exelixis, Inc., H1 2013
- Aduro BioTech, H1 2013
- EpiCep Corporation, H1 2013
- CellDex Therapeutics, Inc., H1 2013
- ImmunoCellular Therapeutics, Ltd., H1 2013
- Lixte Biotechnology Holdings, Inc., H1 2013
- Basilea Pharmaceutica Ltd., H1 2013
Ordering:


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Central Nervous System (CNS) Tumor - Pipeline Review, H1 2013
Web Address: http://www.researchandmarkets.com/reports/2596078/
Office Code: SCD23GGA

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format Type</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [Mr] [Mrs] [Dr] [Miss] [Ms] [Prof]
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World